The experimental anti-inflammatory drug ziltivekimab did not reduce major adverse cardiovascular events compared with a ...

Ziltivekimab's failure in a key trial spurred share sell-offs for Novo and other biotechs, as it suggested trouble for ...

Ziltivekimab ZEUS trial results reveal that Novo Nordisk's IL-6 inhibitor successfully reduced inflammation markers in 6,300 ...

Ziltivekimab failed to reduce the risk of 3-point MACE (HR, 0.99) vs placebo in adults with ASCVD, CKD, and CV inflammation. Topline data were announced from a phase 3 trial evaluating ziltivekimab in ...

Novo Nordisk (NVO) stock dropped 9% after its ZEUS cardiovascular trial failed to meet its primary endpoint, raising questions about ziltivekimab's future.

Novo Nordisk's experimental heart drug failed to reduce heart attacks and strokes in a major Phase 3 trial, dealing a blow to ...